Details for Patent: 12,533,408
✉ Email this page to a colleague
Which drugs does patent 12,533,408 protect, and when does it expire?
Patent 12,533,408 protects MAVENCLAD and is included in one NDA.
This patent has ten patent family members in ten countries.
Summary for Patent: 12,533,408
| Title: | Treatment regimen for the treatment of autoimmune disorders |
| Abstract: | A novel treatment regimen is provided for the treatment of autoimmune disorders. Said novel treatment regimen provides for an efficacious treatment of autoimmune disorders with an advantageous safety profile and/or a high quality of life for the patient. Said novel treatment regimen provides for an advantageous benefit-risk ratio for patients endangered by the risk of infections. |
| Inventor(s): | Ursula Boschert, Urs Wiedemann |
| Assignee: | Merck Patent GmbH |
| Application Number: | US18/748,995 |
|
Patent Claim Types: see list of patent claims | Use; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 12,533,408
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | MAVENCLAD | cladribine | TABLET;ORAL | 022561-001 | Mar 29, 2019 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS IN ADULTS BY ADMINISTERING 2 YEARLY TREATMENT COURSES WHEREIN PATIENTS WHO ARE SEROPOSITIVE TO VZV ARE VACCINATED WITH ZOSTER VACCINE RECOMBINANT, ADJUVANTED BETWEEN THE 1ST AND 2ND TREATMENT COURSE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,533,408
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021342333 | ⤷ Start Trial | |||
| Brazil | 112023003432 | ⤷ Start Trial | |||
| Canada | 3194812 | ⤷ Start Trial | |||
| China | 116916934 | ⤷ Start Trial | |||
| European Patent Office | 4210710 | ⤷ Start Trial | |||
| Israel | 301246 | ⤷ Start Trial | |||
| Japan | 2023541877 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
